Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin
Objective. The present study aimed at investigating the efficacy and safety of intravenous administration of cytarabine supplemented with idarubicin in treating acute myeloid leukemia (AML) patients undergoing first attack and its effects on serum levels of cell adhesion molecules, cytokines in resp...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Chemistry |
| Online Access: | http://dx.doi.org/10.1155/2022/5507328 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555931115716608 |
|---|---|
| author | Jinhua Piao Didi Wang Siying Pei Tangdong Ge Jing Li Pengxia Zhang |
| author_facet | Jinhua Piao Didi Wang Siying Pei Tangdong Ge Jing Li Pengxia Zhang |
| author_sort | Jinhua Piao |
| collection | DOAJ |
| description | Objective. The present study aimed at investigating the efficacy and safety of intravenous administration of cytarabine supplemented with idarubicin in treating acute myeloid leukemia (AML) patients undergoing first attack and its effects on serum levels of cell adhesion molecules, cytokines in response to inflammation, and T cell subset populations in acute myeloid leukemia (AML) patients undergoing first attack. Methods. A total of 88 AML patients eligible for inclusion and exclusion criteria participated in the study and were randomly assigned into the control group (n = 44) in which the patients received intravenous administration of cytarabine and daunorubicin and the study group (n = 44) in which the patients received intravenous administration of cytarabine and idarubicin. Clinical response, incidence of adverse reactions, and quality of life 3 months after therapy were evaluated. Soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), IL-10, and IL-35 were measured by ELISA methods. Phenotypic characteristics of T cell subsets including CD4+, CD8+, CD4+IL-10 Tregs, and CD4+CD25+CD127−Foxp3+ Tregs were analyzed by flow cytometry. Results. The clinical response rate of the study group was better than that of the control group (65.91% vs. 45.45%) (P<0.05). After treatment, the study group revealed significantly lower levels of sICAM-1, sVCAM-1, IL-10, and IL-35, a lower proportion of Tregs, a higher rate of CD4+/CD8+ T cells, along with increased scores of the Karnofsky Performance Scale (KPS) compared with the control group (P<0.05). The incidence rate of adverse reactions in the study group was lower than that in the control group (34.09% vs. 61.36%) (P<0.05). Conclusion. These findings demonstrate that intravenous administration of cytarabine supplemented with idarubicin can improve the immune function and quality of life of AML patients, and this combination drug therapy is effective and safe for AML. |
| format | Article |
| id | doaj-art-8487a03b13914fbf9dcd51aa80130264 |
| institution | Kabale University |
| issn | 2090-9071 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Chemistry |
| spelling | doaj-art-8487a03b13914fbf9dcd51aa801302642025-02-03T05:46:47ZengWileyJournal of Chemistry2090-90712022-01-01202210.1155/2022/5507328Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with IdarubicinJinhua Piao0Didi Wang1Siying Pei2Tangdong Ge3Jing Li4Pengxia Zhang5Key Laboratory of Microecology-Immune Regulatory Network and Related DiseasesBiochemistry Teaching and Research OfficeBiochemistry Teaching and Research OfficeBiochemistry Teaching and Research OfficeBiochemistry Teaching and Research OfficeKey Laboratory of Microecology-Immune Regulatory Network and Related DiseasesObjective. The present study aimed at investigating the efficacy and safety of intravenous administration of cytarabine supplemented with idarubicin in treating acute myeloid leukemia (AML) patients undergoing first attack and its effects on serum levels of cell adhesion molecules, cytokines in response to inflammation, and T cell subset populations in acute myeloid leukemia (AML) patients undergoing first attack. Methods. A total of 88 AML patients eligible for inclusion and exclusion criteria participated in the study and were randomly assigned into the control group (n = 44) in which the patients received intravenous administration of cytarabine and daunorubicin and the study group (n = 44) in which the patients received intravenous administration of cytarabine and idarubicin. Clinical response, incidence of adverse reactions, and quality of life 3 months after therapy were evaluated. Soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), IL-10, and IL-35 were measured by ELISA methods. Phenotypic characteristics of T cell subsets including CD4+, CD8+, CD4+IL-10 Tregs, and CD4+CD25+CD127−Foxp3+ Tregs were analyzed by flow cytometry. Results. The clinical response rate of the study group was better than that of the control group (65.91% vs. 45.45%) (P<0.05). After treatment, the study group revealed significantly lower levels of sICAM-1, sVCAM-1, IL-10, and IL-35, a lower proportion of Tregs, a higher rate of CD4+/CD8+ T cells, along with increased scores of the Karnofsky Performance Scale (KPS) compared with the control group (P<0.05). The incidence rate of adverse reactions in the study group was lower than that in the control group (34.09% vs. 61.36%) (P<0.05). Conclusion. These findings demonstrate that intravenous administration of cytarabine supplemented with idarubicin can improve the immune function and quality of life of AML patients, and this combination drug therapy is effective and safe for AML.http://dx.doi.org/10.1155/2022/5507328 |
| spellingShingle | Jinhua Piao Didi Wang Siying Pei Tangdong Ge Jing Li Pengxia Zhang Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin Journal of Chemistry |
| title | Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin |
| title_full | Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin |
| title_fullStr | Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin |
| title_full_unstemmed | Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin |
| title_short | Changes of Cell Adhesion Molecules and T Cell Subset Populations in Acute Myeloid Leukemia Patients Undergoing Intravenous Administration of Cytarabine Supplemented with Idarubicin |
| title_sort | changes of cell adhesion molecules and t cell subset populations in acute myeloid leukemia patients undergoing intravenous administration of cytarabine supplemented with idarubicin |
| url | http://dx.doi.org/10.1155/2022/5507328 |
| work_keys_str_mv | AT jinhuapiao changesofcelladhesionmoleculesandtcellsubsetpopulationsinacutemyeloidleukemiapatientsundergoingintravenousadministrationofcytarabinesupplementedwithidarubicin AT didiwang changesofcelladhesionmoleculesandtcellsubsetpopulationsinacutemyeloidleukemiapatientsundergoingintravenousadministrationofcytarabinesupplementedwithidarubicin AT siyingpei changesofcelladhesionmoleculesandtcellsubsetpopulationsinacutemyeloidleukemiapatientsundergoingintravenousadministrationofcytarabinesupplementedwithidarubicin AT tangdongge changesofcelladhesionmoleculesandtcellsubsetpopulationsinacutemyeloidleukemiapatientsundergoingintravenousadministrationofcytarabinesupplementedwithidarubicin AT jingli changesofcelladhesionmoleculesandtcellsubsetpopulationsinacutemyeloidleukemiapatientsundergoingintravenousadministrationofcytarabinesupplementedwithidarubicin AT pengxiazhang changesofcelladhesionmoleculesandtcellsubsetpopulationsinacutemyeloidleukemiapatientsundergoingintravenousadministrationofcytarabinesupplementedwithidarubicin |